BCCA Protocol Summary for Palliative Therapy for Advanced Breast Cancer Using Anastrozole (ARIMIDEX®)

Protocol Code: BRAVANAS
Tumour Group: Breast
Contact Physician: Dr. Susan Ellard

ELIGIBILITY:
- First or second line hormonal treatment for advanced breast cancer in postmenopausal women.

EXCLUSION CRITERIA:
- Premenopausal women.
- Patients who have progressed on an alternate aromatase inhibitor (note: may be used by patients who cannot tolerate an alternate aromatase inhibitor).

TESTS: None required.

TREATMENT:

Anastrozole 1 mg po daily until evidence of progression.

PRECAUTIONS:
1. Hepatic dysfunction: Anastrozole is considered safe in mild-to-moderate hepatic dysfunction but has not been studied in severe hepatic dysfunction.

Contact Dr. Susan Ellard or tumour group delegate at (250) 712-3900 or 1-888-563-7773 with any problems or questions regarding this treatment program.

Date Activated: 01 Sept 1998
Date Revised: 01 May 2009 (physician contact revised)

References